A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania.

Mark WeiserLinda LeviStephen Z LevineMeir BialerTawfeeq Shekh-AhmadValentin MateiAlexandru TiuganDiana CirjaliuCristinel SavaEugenia SinitaDaisy ZamoraJohn M Davis

Published in: Bipolar disorders (2017)

Valnoctamide was well tolerated at 1500 mg/d but lacked efficacy in the treatment of symptoms in patients with acute mania. Possible differences between the biological mechanisms of action of valproic acid and valnoctamide are discussed.

Keyphrases

double blind
bipolar disorder
placebo controlled
liver failure
clinical trial
phase iii
respiratory failure
study protocol
drug induced
open label